277 related articles for article (PubMed ID: 29868032)
1. Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.
Zhang L; Yu J; Wei W
Front Immunol; 2018; 9():1087. PubMed ID: 29868032
[TBL] [Abstract][Full Text] [Related]
2. Advances in the treatment of graft-versus-host disease with immunomodulatory cells.
Yu Q; Wang H; Zhang L; Wei W
Int Immunopharmacol; 2021 Mar; 92():107349. PubMed ID: 33486323
[TBL] [Abstract][Full Text] [Related]
3. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
Sinkovics JG
Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
[TBL] [Abstract][Full Text] [Related]
4. Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft
Rayasam A; Drobyski WR
Front Immunol; 2021; 12():779076. PubMed ID: 34899738
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges.
Hefazi M; Bolivar-Wagers S; Blazar BR
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575843
[TBL] [Abstract][Full Text] [Related]
7. Current and future approaches for control of graft-versus-host disease.
Koreth J; Antin JH
Expert Rev Hematol; 2008 Oct; 1(1):111. PubMed ID: 20151032
[TBL] [Abstract][Full Text] [Related]
8. Highlighting the interaction between immunomodulatory properties of mesenchymal stem cells and signaling pathways contribute to Graft Versus Host Disease management.
Mirfakhraie R; Ardakani MT; Hajifathali A; Karami S; Moshari MR; Hassani M; Firouz SM; Roshandel E
Transpl Immunol; 2022 Apr; 71():101524. PubMed ID: 34990789
[TBL] [Abstract][Full Text] [Related]
9. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
[TBL] [Abstract][Full Text] [Related]
10. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
[TBL] [Abstract][Full Text] [Related]
11. Advances in understanding the pathogenesis of graft-versus-host disease.
Zeiser R
Br J Haematol; 2019 Dec; 187(5):563-572. PubMed ID: 31588560
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
13. Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations.
Wu QL; Liu XY; Nie DM; Zhu XX; Fang J; You Y; Zhong ZD; Xia LH; Hong M
J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):477-484. PubMed ID: 26223913
[TBL] [Abstract][Full Text] [Related]
14. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies.
Zeiser R; Marks R; Bertz H; Finke J
Ann Hematol; 2004 Sep; 83(9):551-65. PubMed ID: 15449032
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
17. Have we improved in preventing and treating acute graft-versus-host disease?
Perez L; Anasetti C; Pidala J
Curr Opin Hematol; 2011 Nov; 18(6):408-13. PubMed ID: 21912253
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease.
Prinz I; Koenecke C
Arch Immunol Ther Exp (Warsz); 2012 Jun; 60(3):183-90. PubMed ID: 22476537
[TBL] [Abstract][Full Text] [Related]
19. Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.
Presland RB
Expert Rev Proteomics; 2017 Nov; 14(11):997-1006. PubMed ID: 28974115
[TBL] [Abstract][Full Text] [Related]
20. Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study.
Jurado M; De La Mata C; Ruiz-García A; López-Fernández E; Espinosa O; Remigia MJ; Moratalla L; Goterris R; García-Martín P; Ruiz-Cabello F; Garzón S; Pascual MJ; Espigado I; Solano C
Cytotherapy; 2017 Aug; 19(8):927-936. PubMed ID: 28662983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
